You are here


Genefec™ launched in Sweden

Press release, Bergen, 19 December 2005: NorDiag ASA announced today the launch in Sweden of its DNA based test Genefec™, for detection of colorectal cancer. The product was launched by mailing information about Genefec™ from Capio Sankt Görans Hospital, a subsidiary of NorDiag’s cooperative partner Capio Diagnostics, to about 1000 clinical users in the Stockholm area.

The collaboration with Capio Diagnostics will give NorDiag the opportunity to develop a leading position in the Nordic countries, in DNA based detection of colorectal cancer. About 1 million people worldwide get colorectal cancer every year.

- We are very pleased that Capio has now introduced Genefec™ in Sweden. This is the first step of our international launch of Genefec™. Our partnering model, which we have used in Sweden with Capio, will be NorDiags preferred strategy for rapid market entry in other European countries, says NorDiag’s CEO, Christian Horn.

Genefec™ was launched for the first time in Norway at the end of 2002 and today’s improved 2nd generation product was introduced in April this year. The agreement with Capio Diagnostics was expanded in October to also include Sweden and Denmark, tripling the market potential to more than 200 000 tests annually. Genefec™ is expected to be introduced in Denmark during the first half of 2006.

NorDiag’s patented diagnostic test makes it possible to detect colorectal cancer at an early stage, through finding Ki-ras and p53 genetic mutations, which indicate that a tumour has started to develop.

The agreement between NorDiag and Capio states that the local Capio laboratories in Sweden and Denmark will receive the Genefec™ samples from the patients, register them, and send the samples to NorDiag’s laboratory for analysis. Capio will report results and assist clinicians with support information. According to the agreement Capio Diagnostics will pay NorDiag for each test that is analyzed.

- In the goal of detecting colorectal cancer at an early stage, Genefec™ has real potential to become an important tool together with colonoscopy in detecting and treating colorectal cancer. We are delighted to offer this to our clients; initially this will be in the Stockholm area. We expect that the rest of Sweden and Denmark will soon follow, says Medical Director of Capio Diagnostics, Lars Lundgren.

For more information, please contact:

Christian Horn, CEO, NorDiag ASA, +47 90 16 31 53

Lars Lundgren, Medical Director, Capio Diagnostik AB, +46 70 67 620 30

About Capio
Capio is one of the leading participants at the Health Market in Europe, with agencies in Sweden, Norway, Denmark, Finland, Great Britain, France, Spain and Switzerland. Capio has an annual turn over of NOK 12 billion and has 14 000 employees.

About NorDiag ASA
NorDiag is a biotechnology company with a focus on the early detection of cancer. The company’s first product is Genefec™, a genetic test for early detection of gastro intestinal cancer, including colorectal cancer. NorDiag is listed at the Oslo Stock Exchange with the ticker NORD